Remaining Challenges in the Treatment of Relapsed Wilms Tumor: Children's Oncology Group and International Society of Paediatric Oncology Perspectives

Wilms tumor (WT) is the most common pediatric renal tumor, and with multidisciplinary treatment overall outcomes are excellent. However, a small subset of patients with WT will relapse. The ideal treatment of relapsed WT is yet to be defined. Ongoing studies through the Children's Oncology Group Renal Tumors Committee (COG-RTC) and the International Society of Paediatric Oncology Renal Tumor Study Group (SIOP-RTSG) aim to improve risk stratification and treatment strategies. Members met at the SIOP 55th Annual Congress 2023 to outline available data and knowledge gaps and develop future research priorities.

Authors

Institutions

Publication Details

Journal
Pediatric Blood & Cancer
Published
2025-05-14
DOI
https://doi.org/10.1002/pbc.31790
Citations
2
Primary Topic
Renal and related cancers
Type
article
Field-Weighted Citation Impact
1.61

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Remaining Challenges in the Treatment of Relapsed Wilms Tumor: Children's Oncology Group and International Society of Paediatric Oncology Perspectives

Amy L. Walz, Jack Brzezinski, Filippo Spreafico, Luke Pater et al.
2 citations
Pediatric Blood & Cancer
Renal and related cancers
1.61
article

Remaining Challenges in the Treatment of Relapsed Wilms Tumor: Children's Oncology Group and International Society of Paediatric Oncology Perspectives

Amy L. Walz, Jack Brzezinski, Filippo Spreafico, Luke Pater, Norbert M. Graf, Jan Godziński, Marry M. van den Heuvel‐Eibrink, Rhoikos Furtwängler, Jesper Brok, Max Pachl, Justine N. van der Beek, Elizabeth Anne Mullen, Alissa Groenendijk, Peter F. Ehrlich, Andrew J. Murphy, James I. Geller, Geert O. Janssens, Kathryn S. Sutton, Marc H.W.A. Wijnen
article en
2 citations

Abstract

Wilms tumor (WT) is the most common pediatric renal tumor, and with multidisciplinary treatment overall outcomes are excellent. However, a small subset of patients with WT will relapse. The ideal treatment of relapsed WT is yet to be defined. Ongoing studies through the Children's Oncology Group Renal Tumors Committee (COG-RTC) and the International Society of Paediatric Oncology Renal Tumor Study Group (SIOP-RTSG) aim to improve risk stratification and treatment strategies. Members met at the SIOP 55th Annual Congress 2023 to outline available data and knowledge gaps and develop future research priorities.

Pediatric Blood & CancerVol. 72(8)
Northwestern University (US), Cincinnati Children's Hospital Medical Center (US), Boston Children's Hospital (US), Lurie Children's Hospital (US), St. Jude Children's Research Hospital (US), Emory University (US), University of Toronto (CA), University of Washington (US), University of Wrocław (PL), University of Michigan (US), University Hospital of Bern (CH), Hospital for Sick Children (CA), Rigshospitalet (DK), University Medical Center Utrecht (NL), Wroclaw Medical University (PL), Szpital im Tadeusza Marciniaka (PL), Birmingham Children's Hospital (GB), Aflac (United States) (US), Dana-Farber Cancer Institute (US), Princess Máxima Center (NL), SickKids Foundation (CA), Children's Healthcare of Atlanta (US), C. S. Mott Children's Hospital (US), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), Wilhelmina Children's Hospital (NL), University of Cincinnati (US), University of Birmingham (GB), Saarland University (DE)
St. Baldrick's Foundation
Partnerships for the goals
Openalex Percentile: Top 17%
Renal and related cancers
1.61
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.